Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

被引：43
作者：
Roex, Gils [1 ]
Feys, Tom [2 ]
Beguin, Yves [3 ]
Kerre, Tessa [4 ]
Poire, Xavier [5 ]
Lewalle, Philippe [6 ]
Vandenberghe, Peter [7 ]
Bron, Dominique [6 ]
Anguille, Sebastien [1 ,8 ,9 ]
机构：
[1] Univ Antwerp, Tumor Immunol Grp, Lab Expt Hematol, Vaccine & Infect Dis Inst VAXINFECTIO, B-2650 Edegem, Belgium
[2] Ariez Int BV, B-9000 Ghent, Belgium
[3] Univ Liege, Dept Hematol, B-4000 Liege, Belgium
[4] Univ Hosp Ghent, Dept Hematol, B-9000 Ghent, Belgium
[5] Catholic Univ Louvain, Fac Med & Dent, B-1200 Woluwe St Lambert, Belgium
[6] Inst Jules Bordet, Dept Hematol, B-1000 Brussels, Belgium
[7] Univ Hosp Leuven, Dept Hematol, B-3000 Leuven, Belgium
[8] Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med CCRG, B-2650 Edegem, Belgium
[9] Antwerp Univ Hosp, Div Hematol, B-2650 Edegem, Belgium
来源：
PHARMACEUTICS | 2020年 / 12卷 / 02期
关键词：
CAR-T cells; immunotherapy; B-cell malignancies; CD19; BCMA; MULTIPLE-MYELOMA; BCMA; EXHAUSTION; REMISSIONS; EXPRESSION; MANAGEMENT; LYMPHOMA; GROWTH; 4-1BB;
D O I：
10.3390/pharmaceutics12020194
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
引用
收藏
页数：15
相关论文
共 82 条
[1]   Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas [J].
Abramson, Jeremy S. ;
Palomba, Maria Lia ;
Gordon, Leo I. ;
Lunning, Matthew A. ;
Wang, Michael L. ;
Arnason, Jon E. ;
Mehta, Amitkumar ;
Purev, Enkhtsetseg ;
Maloney, David G. ;
Andreadis, Charalambos ;
Sehgal, Alison R. ;
Solomon, Scott R. ;
Ghosh, Nilanjan ;
Albertson, Tina ;
Garcia, Jacob ;
Kostic, Ana ;
Li, Daniel ;
Kim, Yeonhee ;
Siddiqi, Tanya .
BLOOD, 2019, 134
[2]   CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). [J].
Abramson, Jeremy S. ;
Palomba, Maria Lia ;
Gordon, Leo I. ;
Lunning, Matthew Alexander ;
Arnason, Jon E. ;
Forero-Torres, Andres ;
Wang, Michael ;
Albertson, Tina M. ;
Allen, Tara ;
Sutherland, Claire ;
Xie, Benhuai ;
Garcia, Jacob ;
Siddiqi, Tanya .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3]   Strategies to Address Chimeric Antigen Receptor Tonic Signaling [J].
Ajina, Adam ;
Maher, John .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (09) :1795-1815
[4]   T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].
Ali, Syed Abbas ;
Shi, Victoria ;
Maric, Irina ;
Wang, Michael ;
Stroncek, David F. ;
Rose, Jeremy J. ;
Brudno, Jennifer N. ;
Stetler-Stevenson, Maryalice ;
Feldman, Steven A. ;
Hansen, Brenna G. ;
Fellowes, Vicki S. ;
Hakim, Frances T. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
BLOOD, 2016, 128 (13) :1688-1700
[5]  
[Anonymous], 2018, BLOOD S1, DOI DOI 10.1182/blood-2018-99-117199
[6]  
[Anonymous], 2017, HEMATOL ONCOL, DOI [DOI 10.1002/HON.2437_6, 10.1002/hon.2437_6]
[7]   CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). [J].
Abramson, Jeremy S. ;
Palomba, Maria Lia ;
Gordon, Leo I. ;
Lunning, Matthew Alexander ;
Arnason, Jon E. ;
Forero-Torres, Andres ;
Wang, Michael ;
Albertson, Tina M. ;
Allen, Tara ;
Sutherland, Claire ;
Xie, Benhuai ;
Garcia, Jacob ;
Siddiqi, Tanya .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8]  
[Anonymous], 2019, HEMATOL ONCOL, DOI DOI 10.1002/HON.110_2630
[9]  
[Anonymous], 2018, BLOOD S1, DOI [DOI 10.1182/blood-2018-99-114152, DOI 10.1182/BLOOD-2018-99-114152]
[10]   Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study [J].
Ardeshna, Kirit M. ;
Marzolini, Maria A. V. ;
Norman, Jane ;
Al-Hajj, Muhammad ;
Thomas, Simon ;
Faulkner, Jim ;
Kotsopoulou, Ekaterini ;
Pule, Martin ;
Peddareddigari, Vijay G. R. ;
Khokhar, Nushmia Z. ;
Jonnaert, Maud ;
Chen, Robert ;
Osborne, Wendy .
BLOOD, 2019, 134
123456789